Insights from
UBC's Expert Voices

UBC talked with Josh Hardman, founder of Psychedelic Alpha, to discuss the evolving landscape of psychedelic drug development—from shifting regulatory expectations to the role of psychotherapy and the impact of stigma on patient access. Hardman shares a clear-eyed perspective on where the field stands today, the scientific rigor needed to advance it, and what he’s watching most closely as the industry moves toward potential first approvals.

As we look ahead to 2026, patient access and support services face growing complexity—from affordability challenges and evolving care models to the rise of specialty therapies. This blog explores the key trends shaping the healthcare landscape and offers strategic solutions, including AI-powered innovation, digital transformation, and partnerships that drive better outcomes. Discover how UBC is leading the way with patient-first strategies to simplify the patient and product journey.

AI is no longer just a buzzword—it’s a practical tool shaping how we work every day. Learn how UBC leverages AI models to streamline tasks, enhance decision-making, and maintain compliance.

Modern medical record retrieval is transforming real-world evidence. Datavant’s approach combines nationwide reach, deep data connectivity, and high record yields to deliver comprehensive, research-ready datasets.

UBC attended the 2025 NORD Rare Diseases & Orphan Products Breakthrough Summit, where patient voices, scientific innovation, and regulatory expertise converged to shape the future of rare-disease research. Learn what inspired us and how we’re advancing real-world evidence, patient partnerships, and innovative trial designs to accelerate progress for the rare-disease community.

As cell and gene therapies reshape treatment paradigms, patient support programs must evolve to meet new challenges. Discover how strategic alignment, payer advocacy, and innovative solutions can optimize the patient journey.

UBC recently completed a multi-country feasibility assessment to identify disease registries capable of supporting a PASS for a novel therapy targeting a hereditary muscular disorder. The study evaluated registry data elements, quality, and governance to ensure fit-for-purpose real-world data (RWD) for generating reliable RWE.

Learn how companies are making the most of their oversight capabilities by leveraging real-time data to improve the health of their pharmacovigilance program.

AI is revolutionizing drug safety, but without proper guardrails, it can introduce new risks. Learn how risk-based integration strategies are helping life sciences companies harness AI’s power while maintaining trust, transparency, and compliance.